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Objectives: To build a predictive model of acceptance of drugs to the United 
Kingdom’s (UK) Cancer Drugs Fund (CDF) based on the scores for each factor 
published in the public decision summaries. MethOds: All decision summaries 
published from December 2014 until May 2015 were included. For each decision 
summary, data were collected regarding the drug indication, scores for each decision 
factor (progression-free survival: PFS, overall survival: OS, quality-of-life: QoL, and 
unmet need), total clinical score, strength of evidence, cost, and decision outcome. 
Decisions to either retain or place drugs on formulary were counted as positive 
decisions; all other decisions were classified as negative decisions. A generalised 
linear model (GLM) was used to estimate the odds of each factor resulting in a 
positive decision; univariate and multivariate analyses were performed. Results: 
62 decisions were issued in the study period for a total of 34 different drugs; 2 
drugs were not formally assessed due to a lack of comparison against the standard 
of care in the UK. Only 22 of 64 (34.4%) of drugs received positive decisions from 
the CDF since December 2014, with an average total clinical score of 2.85. Median 
PFS and OS scores were 2 and 0, respectively, indicating most drugs did not have 
significantly improved OS as assessed by the CDF. Univariate results from the GLM 
demonstrated that PFS and OS gains resulted in higher odds of approval with odds 
ratios of 1.56 (95%CI:1.15-2.22) and 1.63 (95%CI:1.11-2.71), respectively. A multivariate 
analysis also demonstrated significant effects of PFS (OR:2.12,95%CI:1.43-3.50), OS 
(OR:2.35,95%CI:1.19-6.97), and a trend for QoL (OR:2.58,95%CI:0.73-9.93). Monthly 
cost was not a significant predictor of outcome in the model. cOnclusiOns: The 
majority of decisions since the 2015-2016 CDF procedures update have been nega-
tive; greater gains in PFS and OS significantly improved the likelihood of a positive 
CDF review outcome.
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Objectives: Since 2011, the number of health technology assessments (HTAs) on 
pharmacological therapies increases annually. As countries worldwide are trying 
to curb overall healthcare expenditure, the objective of this study was to analyse 
if this upward trend is also found in the area of medical devices. MethOds: One 
hundred HTA agencies were selected. Their reports on medical devices since 2011 
were analyzed by number and type and matched with HTAs for pharmacological 
therapies. Results: Not all of the included agencies assess medical devices. Most 
device HTAs are carried out in the UK, France, Sweden, the US and Australia, match-
ing their overall high HTA activity. However, other countries with high drug HTA 
activity (Germany, Spain, the Netherlands) focus less on devices. Most device-related 
HTAs are indicated for cardiovascular diseases, while pharmaceuticals are domi-
nated by oncology. The number of HTAs on pharmacological therapies increases 
every year (with seasonality), while the number of device HTAs remained steady over 
the last 5 years. Generally, HTA agencies seem to perform device evaluations more 
on an ad-hoc basis. cOnclusiOns: Although the total number of HTAs performed 
worldwide is increasing, the number of device assessments remained fairly stable. 
However, manufacturers seem to realize HTA importance and need to adapt to EU 
regulations. The increased clinical requirements in the draft EU Medical Devices 
Regulation will enable manufacturers to find their role in this growing area.
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Objectives: The rise in molecular diagnostic testing in oncology has made these 
tests the subject of an increasing number of investment discussions, reimbursement 
negotiations and hospital cost calculations. This requires a detailed assessment 
of the total cost for determining tumor mutation status beyond plain kit costs. 
This research maps the workflow, identifies investment needs and quantifies the 
direct variable costs of KRAS and NRASmutation testing from formalin fixed paraf-
fin embedded (FFPE) sample to result. MethOds: The complete test workflow is 
based on the current workflow in two academic European institutions. Hands-on 
time and consumables used in each step were quantified in both hospitals. Unit 
cost was obtained from the finance departments. Results: Costs related to tumor 
mutation tests include investments (lab space, lab equipment, molecular diagnostic 
systems, training, quality assurance, accreditation), indirect costs, lab running costs 
(disinfection, cost of errors and repeats) and direct variable costs including reagent 
costs, controls and labor. The total cost depends on workflow and tumor profile. To 
detect a wild-type RAS tumor, the direct variable costs from FFPE sample to result 
excluding reagent costs, is estimated at € 64 using a CE-IVD kit for KRAS exon 2 
followed by pyrosequencing for NRAS exon 2 and extended RAS testing, € 51 using 
High Resolution Melting confirmed by pyrosequencing and € 3 for an automated 
instrument. The latter automated technology includes sample preparation in the 
test cost, as it works directly from FFPE. cOnclusiOns: Estimations on the cost 
of performing tumor mutation tests should include not only reagent costs, which 
are usually considered, but also investments, lab running costs, labor and all other 
direct and indirect costs. Even in the most advanced labs, efforts are needed to fully 
and subsequent clinical outcomes in chemotherapy-naïve mCRPC. MethOds: 
COU-AA-302 was a multinational, double-blind, randomized phase 3 trial of abira-
terone acetate plus prednisone compared with prednisone alone in asymptomatic 
or mildly symptomatic mCRPC patients without previous chemotherapy. Using 
data from the entire COU-AA-302 patient population (N = 1088) over the first 181 
days of treatment, we explored the relationships between clinical time-to-event 
end points and changes in PROs measuring pain, physical well-being (PWB), func-
tional well-being (FWB), and prostate cancer–specific signs and symptoms. Cox 
regression models were developed to assess the relationship between each PRO 
(separately and for all 4 simultaneously), and radiographic progression-free survival 
(rPFS) as the dependent variable, adjusting for important baseline clinical and PRO 
characteristics. Results: In each individual model, patients with worsening PROs 
were at greater risk of radiographic progression compared with patients whose 
PRO scores improved or remained stable during the follow-up period. Hazard ratios 
(95% confidence intervals) for worsening pain intensity, PWB, FWB, and prostate 
cancer–specific symptoms were 1.68 (1.28-2.21), 2.08 (1.60-2.71), 1.35 (1.04-1.74), and 
1.52 (1.18-1.95), respectively (all p ≤ 0.02). When all 4 PRO end points were included 
in a single multivariate model, a worsening in PWB was the most significant factor 
associated with worse rPFS. There were too few events at the time of analysis cut-
off to explore the relationship between survival and PROs. cOnclusiOns: These 
results demonstrate a significant temporal relationship between PROs and disease 
progression. Worsening of PROs was associated with an increased likelihood of 
radiographic progression. In addition to their traditional utility in describing patient-
relevant outcomes in clinical trials, PROs may be valuable clinical monitoring tools 
when following patients for disease progression.
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Objectives: The Israeli National Health Insurance Law stipulates a National List 
of Health Services (NLHS) which all residents are entitled to. Every year, the govern-
ment determines the additional budget to be allocated for new health technologies 
on the NLHS. A public national advisory committee (PNAC) evaluates and prioritizes 
all proposed technologies. The PNAC takes into account mainly the efficacy of the 
new technology, but also economic, social and ethical aspects. However, until now, 
no standard tool was available for grading the extent of benefit of therapies. The 
European Society for Medical Oncology (ESMO) published recently its Magnitude 
of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. The scale is graded 5, 
4, 3, 2, 1, for treatments of advanced/metastatic cancers (the ‘palliative setting’), 
where grades 5 and 4 represent the highest level of proven clinical benefit. Our 
objective was to examine, in retrospect, whether the novel cancer drugs that were 
recommended for reimbursement by the PNAC, had higher ESMO-MCBS scores 
than the candidate drugs that were not approved in the 2015 NLHS update pro-
cess. MethOds: ESMO-MCBS scores were obtained for the cancer drugs that were 
candidates for the 2015 NLHS update. Fisher’s Exact Test was used to compare scores 
of drugs approved and those not approved for reimbursement. Results: 17 cancer 
drugs were candidates for the 2015 NLHS update deliberations. An ESMO-MCBS 
score was available for 5/7 approved drugs and 8/10 non-approved drugs. 80% of the 
approved drugs and none of the non-approved drugs gained a score> = 3 (p= 0.007). 
Median scores were 3 and 1 respectively. cOnclusiOns: The Israeli PNAC’s deci-
sions regarding reimbursement for novel cancer drugs seem to be in concordance 
with ESMO-MCBS scores. The structured and consistent approach of the ESMO-
MCBS could further assist in framing the appropriate use of limited public resources 
to deliver effective and affordable cancer care.
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Objectives: When people die due to cancer, their contribution to society through 
paid work, called production, is lost. Previous estimates of cancer-related lost 
production have focussed on developed countries. However, developing nations 
account for approximately 70% of the world’s annual cancer deaths. We estimate 
the value of lost productivity due to cancer mortality in the rapidly emerging econo-
mies of Brazil, Russia, India, China and South Africa (BRICS) and compare it to 
the UK. MethOds: Based on the Human Capital Approach, we valued the lost 
productivity associated with premature cancer deaths in BRICS countries and the 
UK in 2012. We used GLOBOCAN estimates of cancer deaths by country, sex and 
age group, along with OECD and national data for workforce participation, unem-
ployment, and wage rates. Sensitivity analyses examined the impact of changing 
assumptions about wages, life expectancy and discounting. Results: The total 
cost of cancer-related lost productivity in the UK in 2012 was € 3 billion, and in 
the BRICS countries combined was over € 24 billion. Losses were highest in China 
(€ 12.9 billion) and lowest in South Africa (€ 0.9 billion). When adjusted by number of 
deaths, lost productivity (per death) were highest in South Africa (€ 19,000), the UK 
(€ 19,000), and Brazil (€ 14,000) and lowest in India (€ 3,000). There were large differ-
ences between countries in terms of lost productivity when examined by gender, age 
and cancer. For example, the cancers contributing highest productivity losses were 
lung cancer in Russia (22% of total), South Africa (14%), Brazil (13%) and the UK (11%), 
stomach cancer in India (11%), and liver cancer in China (31%). cOnclusiOns: 
In many developing countries cancer now kills more people than AIDS, malaria 
and tuberculosis combined, however resources have not shifted correspondingly. 
Valuing cancer-related lost productivity provides policy-makers with an additional 
perspective on priorities for cancer prevention and control.
